An electrical & electronics engineer by qualification, Shikha Sinha has been working in the research and content domains for quite a while. Currently penning down informative pieces for page125.org, Shikha is also an active contributor on a variety of business portals spanning healthcare, ICT, renewables, etc. While she isn’t harnessing the power of the pen, Shikha loves to cook, read, and travel. She can be contacted at- [email protected] | https://twitter.com/shikhas999/
U.S. biotechnology firm, United Therapeutics Corp. has recently invested $800 million cash upfront to grab rights to Arena Pharmaceuticals’ pulmonary arterial hypertension (PAH) drug, Ralinepag. As per sources, the firm’s executive crew believes that the acquired rights would enable the company to gain huge revenues …
The Ministry of Science and Technology has recently announced that India and the United Kingdom have both signed a Memorandum of Understanding (MoU) for collaborating on cancer research at the Inaugural Researchers’ Conference in New Delhi. The India-UK Cancer Research Initiative focused on developing affordable …
IMV Incorporation, a clinical stage biopharmaceutical company, has reportedly declared the expansion of its clinical program through a Phase 2 basket trial assessing its prime drug, DPX-Survivac, combined with KEYTRUDA (pembrolizumab) and cyclophosphamide, in patients suffering from recurrent or advanced solid tumors. Frederic Ors, Chief …
Silence Therapeutics PLC, a UK based biotechnology firm, has reportedly grabbed headlines by announcing the launch of its first-in-human clinical test, anticipated to kick off in the second half of 2019. For the record, Silence Therapeutics boasts of expertise in RNA interference, which is a …
Roche, a Swiss multinational healthcare company, has reportedly made it to the headlines with regards to its drug pricing issue in Britain. According to sources familiar with the matter, NICE (National Inst. for Health & Care Excellence) has disapproved its drug ‘Ocrevus’ on the grounds …
Aurobindo Pharma, the second-biggest drugmaker in India, recently announced that it has agreed to buy Sandoz’s dermatology business and a portfolio of its oral solid products in U.S., as well as manufacturing and commercial infrastructure for a total of $900 million. As part of the …
Pfizer recently made an announcement confirming that its experimental oral inhibitor, Janus kinase 3 (JAK3) or PF-06651600, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Apparently, the inhibitor is being developed for treating patients suffering from alopecia areata, …
The National Health Service (NHS), the national healthcare system of England, has reportedly made plans to treat young people and children stricken with cancer with a costly yet revolutionary cancer drug, which has enormous potential to transform the way this disease is treated. According to …
Researchers at the University of Colorado Boulder have reportedly developed an unconventional genetic disruption strategy that successfully stymies the growth of antibiotic-resistant bacteria, giving scientists an edge over deadly superbugs. According to data from the Centers for Disease Control, these multiple drug resistant pathogens — …
